April 25, 2022
Name of listed company: | Chugai Pharmaceutical Co., Ltd. |
Code number: | 4519 (Prime Market of Tokyo Stock Exchange) |
Head office: | 1-1, Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo |
President & CEO: | Osamu Okuda |
Inquiries to: | Toshiya Sasai |
Head of Corporate Communications Dept. | |
Tel: +81-(0)3-3273-0554 |
F. Hoffmann-La Roche Announces First Quarter Sales 2022
F. Hoffmann-La Roche Ltd. (hereafter "Roche") [Head Office: Basel, Switzerland. CEO: Severin Schwan] announced today its first quarter sales 2022 (January 1 - March 31, 2022).
Roche owns 59.89% of Chugai's outstanding shares (61.16% of voting rights) as of the end of December 2021.
Its investor update and presentation materials can be found on its website(https://www.roche.com/).
Chugai's performance for the period of January 1 to March 31, 2022 is included in the announced Roche Group's results.
Investor Updates
Reporting
###
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Chugai Pharmaceutical Co. Ltd. published this content on 25 April 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 April 2022 05:08:00 UTC.